Enveric Biosciences Inc. said on Friday it has agreed to sell one of its cancer-related patent portfolios. The Cambridge, Massachusetts-based company didn’t disclose the amount. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe and Japan, with patent applications pending in Canada, Israel, and Korea, the company said in a press release.
